Abstract
Hypertension is one of the leading risk factors for cardiovascular disease and represents a major health and economic burden. Most patients with high-or very high-risk hypertension have multiple cardiovascular risk factors with or without accompanying subclinical organ damage or established cardiovascular or renal disease. Patients with severe hypertension or with moderate hypertension and one to two additional risk factors have absolute 10-year risks of cardiovascular disease of 21–30% and 15–20%, respectively. Current European treatment guidelines recommend that antihypertensive therapy be initiated rapidly and aggressively in patients with high-risk hypertension. Most patients require two or more antihypertensive agents to achieve the strict blood pressure target of <130/80 mmHg. This article reviews the existing cost-effectiveness data on the use of angiotensin II receptor antagonists (blockers) [ARBs] in patients with high-risk hypertension. Aggressive ARB treatment of patients in the early (microalbuminuric) stages of diabetic nephropathy has a significant renoprotective effect, delaying the onset of overt (proteinuric) nephropathy. By slowing the progression of these patients to end-stage renal disease, substantial cost savings can be made. There is a paucity of cost-effectiveness data regarding the use of fixed-dose ARB plus thiazide diuretic combination therapies. Longitudinal cost-benefit studies of this attractive and efficacious first-line treatment option are needed.
References
Ezzati M, Lopez AD, Rodgers A, et al., and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21; 365(9455): 217–23
Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics 2004; 22(14): 907–28
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87
Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005 Dec; 26(24): 2616–22
Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991 Jan; 83(1): 356–62
Martín-Baranera M, Campo C, Coca A, et al. Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population: results of the DICOPRESS study [in Spanish]. Med Clin (Barc) 2007; 129(7): 247–51
Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 Jun; 24(11): 987–1003
Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18(3): 139–85
Council of the European Union. 2586th Council Meeting —Employment, Social Policy, Health and Consumer Affairs. Luxembourg 2004 Jun 1–2 [online]. Available from URL: http://ue.eu.int/Newsroom/ [Accessed 2007 Jun 13]
Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006 Jul; 27(13): 1610–9
American Heart Association. Heart disease and stroke statistics: 2005 update [online]. Available from URL: httpV/www.americanheart. org/downloadable/heart/1105390918119HDSStats 2005Update.pdf [Accessed 2007 Jun 13]
Organisation for Economic Co-operation Development. OECD health data 2004: a comparative analysis of 30 countries. 2nd ed. [online]. Available from URL: http://www.oecd.org/ health/healthdata/ [Accessed 2007 Jun 13]
Kiiskinen U, Vartiainen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998 Aug; 16(8): 1103–12
Puska P, Tuomilehto J, Nissinen A, et al., editors. The North Karelia project: 20 year results and experiences. Helsinki: The National Public Health Institute (KTL), 1995
Roca-Cusachs A, Dalfo A, Badia X, et al. Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001 Oct; 19(10): 1913–9
Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: a population-based study. J Clin Epidemiol 1996; 49(11): 1239–45
Dimenäs ES, Wiklund IK, Dahlöf CG, et al. Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989; 7(11): 885–90
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363(9426): 2022–31
Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10–16; 366(9489): 895–906
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72
Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006 Dec; 8(12): 850–7
Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004 Nov; 6(11): 614–20
Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62(13): 1983–2005
Bonner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004 May; 20(5): 597–602
Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8(2): 114–21
Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999 Apr–May; 53(3): 175–8
Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26Suppl. A: A33–7
Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 Nov 4; 351(19): 1941–51
Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005 Feb; 45(2): 281–7
Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 870–8
Michaels JA. Improving NICE’s social value judgments. BMJ 2006 Jan 7; 332(7532): 48–50
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 995–1003
McInnes G, Burke TA, Carides G. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2006 Jan; 20(1): 51–8
Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003 Mar; 26(3): 683–7
Palmer AJ, Annemans L, Roze S, et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int 2005 Jan; 93 Suppl.: S52–4
Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003 Jul; 25(7): 2102–19
Palmer AJ, Valentine WJ, Tucker DM, et al. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin 2006 Nov; 22(11): 2095–100
Palmer AJ, Roze S, Valentine WJ, et al. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Med Wkly 2006 May 27; 136(21-22): 346–52
Palmer AJ, Tucker DM, Valentine WJ, et al. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005 Jun; 20(6): 1103–9
Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004 Oct; 18(10): 733–8
Palmer AJ, Chen R, Valentine WJ, et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab 2006 Feb; 32(1): 69–76
McMurray JJ, Andersson FL, Stewart S, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006 Jun; 27(12): 1447–58
Reed SD, Friedman JY, Velazquez EJ, et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004 Jul; 148(1): 122–8
Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail 2005 May; 11(4): 253–9
Reed SD, Radeva JI, Weinfurt KP, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J 2005 Aug; 150(2): 323–9
Hilleman DE, Wurdeman RL, Lenz TL. Cost-effectiveness evaluation of fixed-dose combination of angiotensin-II receptor blockers with and without hydrochlorothiazide. Am J Hypertens 2001; 14Suppl. 1: A112–A3
Boersma C, Atthobari J, Gansevoort RT, et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 2006; 24(6): 523–5
Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004 Jul; 148(1): 52–61
Rudd P. Compliance with antihypertensive therapy: raising the bar of expectations. Am J Manag Care 1998; 4: 957–66
Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2007; 62(1): 76–87
After the diagnosis: adherence and persistence with hypertensive therapy. Am J Manag Care 2005; 11 (13 Suppl.): S395-9
Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005 Nov; 23(11): 2093–100
Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004 Dec; 22(12): 2379–86
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288(23): 2981–97
Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345(12): 861–9
Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345(12): 851–60
Acknowledgements
The author would like to thank Natalie Barker of Wolters Kluwer Health Medical Communications (funded by Bristol-Myers Squibb) for her assistance in writing and editing this review. The author has received research grants and honoraria for advisory tasks from sanofi-aventis and Bristol-Myers Squibb.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coca, A. Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers). Clin. Drug Investig. 28, 211–220 (2008). https://doi.org/10.2165/00044011-200828040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200828040-00002